Company Overview and News
KUALA LUMPUR (Sept 2): The FBM KLCI pared some of its gains at mid-morning today in line with the nervy regional markets.
MarketWatch: Wall Street will fixate on a wave of US economic data this week, crested by payrolls data on Friday that could sway expectations about the timing of future interest rate hikes and spark volatility in record-high stock prices. Fresh data about employment and consumer confidence could help investors solidify expectations for a December interest rate hike from the US Federal Reserve, or lend weight to a minority of strategists predicting a rate rise as early as next month.
KUALA LUMPUR (July 21): The FBM KLCI fell 0.39% at mid-morning today, weighed by losses at select blue chips including Petronas-linked stocks.
KUALA LUMPUR (July 14): The FBM KLCI edged lower today, despite the rally at regional markets as sellers outpaced buyers as local investors paused for a breather.
KUALA LUMPUR, July 14 — Shares on Bursa Malaysia slipped further into the red at mid-morning today, weighed on by losses in selected blue chips, dealers said.
KUALA LUMPUR (July 14): The FBM KLCI remained in negative territory at mid-morning despite analysts being positive on Bank Negara Malaysia easing its monetary policy.
KUALA LUMPUR (June 7): The FBM KLCI edged up marginally higher this morning in line with the gains at the regional markets, lifted by select by blue chips including Petronas-linked stocks.
KUALA LUMPUR (April 26): The FBM KLCI fell 0.62% at mid-morning in line with the weaker regional markets, extending its consolidation.
KUALA LUMPUR (April 25): The FBM KLCI dipped 0.31% at the midday break today as sentiment remained lacklustre at the local market in line with the drop at most regional markets.
KUALA LUMPUR (April 25): The FBM KLCI remained lacklustre at mid-morning today in line with the weaker regional markets, weighed by select blue chips.
KUALA LUMPUR (March 10): The FBM KLCI rose 0.29% at the midday break today in line with the uptrend at most regional markets, but gains are seen limited with little fresh catalysts to boost the local market. At 12.30pm, the FBM KLCI rose 4.91 points to 1,691.26. The index had earlier dipped to its intra-morning low of 1,684.10. Market breadth was mixed with 353 gainers and 291 losers, while 336 counters traded unchanged.
KUALA LUMPUR (Feb 23): The FBM KLCI pared some of its gains at the midday break in line with the retreat at most regional markets. At 12.30pm, the FBM KLCI was up 8.91 points at 1,683.50. The index had earlier risen to its intra-morning high of 1,685.88. Gainers led losers by 399 to 312, while 333 counters traded unchanged. Volume was 1.08 billion shares valued at RM862.22 million.
KUALA LUMPUR, Feb 16 ― The benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) opened higher in the early session today, lifted by fresh buying appetite in heavyweights and external factors including an oil price rebound. At 9.15am, the FBM KLCI was
KUALA LUMPUR (Jan 20): The FBM KLCI stayed in the negative zone at the midday break today, in line with the regional markets that retreated. Sentiment at the local bourse also remained tepid, as investors turned bearish. At 12.30pm, the FBM KLCI fell 6.87 points to 1,622.35. Losers hammered gainers by 706 to 141, while 248 counters traded unchanged. Volume was 1.24 billion shares, valued at RM909.93 million.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...